The article focuses on the FDA's (U.S. Food and Drug Administration) emergency use authorization of pemivibart (Pemgarda), a long-acting monoclonal antibody, for COVID-19 preexposure prophylaxis in immunocompromised individuals who cannot mount adequate immune responses to vaccines.